Acrivon Therapeutics (ACRV) investor relations material

AP3 Platform and Pipeline Overview

• The AP3 generative phosphoproteomics platform enables direct identification of drug effects on disease pathways, predictive biomarkers, and supports indication finding, resistance mechanism identification, and patient responder selection, fueling the clinical and preclinical pipeline.

• Lead assets include phase II-B CHK1/2 inhibitor ACR-368, phase I dual WEE1/PKMYT1 inhibitor ACR-2316, and preclinical CDK11-targeting ACR-6840.

• AP3-driven programs are expanding into auto-immune/inflammatory indications and additional oncology targets.

ACR-368 Phase II-B/2b Study in Endometrial Cancer

• ACR-368 OncoSignature predicts benefit in biomarker-positive endometrial cancer, with a 39% overall response rate and over 80% disease control rate in arm one.

• Serous subtype demonstrated a 67% confirmed response rate in biomarker-positive patients and 52% in all-comers with up to two prior therapies.

• Arm three, enrolling up to 90 all-comer serous subjects in the US and EU, is ongoing with completion expected Q4 2026 and initial data update in mid-2026.

• Subjects in Arm 3 will receive ACR-368 with ULDG sensitization, which may further increase response rates.

• Phase III trial protocol for ACR-368 plus anti-PD-1 submitted to FDA, with global trial readiness anticipated mid-2026.

Market Opportunity and Clinical Context

• Serous endometrial cancer accounts for 40% of endometrial cancer deaths, with a prevalence pool of 55,000-60,000 patients in the US and EU.

• Current second- and third-line therapies offer limited benefit, with response rates of 10-15% and PFS of 2.5-3.5 months.

• ACR-368's differentiated tolerability profile and high response rates position it competitively against ADCs, especially in later lines.